Endpoints News reports that the agreement covers a trispecific T-cell engager for multiple myeloma and marks GSK’s second deal with the Chinese biotech.
GSK is paying up to $750 million for Chimagen’s trispecific T-cell engager for multiple myeloma, a blood cancer, Endpoints News reports. The agreement is GSK’s second T-cell engager deal with the Chinese biotech.
3K
1 post, first seen 23h ago
Endpoints News reports that the agreement covers a trispecific T-cell engager for multiple myeloma and marks GSK’s second deal with the Chinese biotech.
GSK is paying up to $750 million for Chimagen’s trispecific T-cell engager for multiple myeloma, a blood cancer, Endpoints News reports. The agreement is GSK’s second T-cell engager deal with the Chinese biotech.
Endpoints News@endptsGSK is paying up to $750M for Chimagen's trispecific T cell engager, its second deal with the Chinese biotech, this time in multiple myeloma.
Not enough discussion yet.
No sentiment analysis available yet.
Not enough discussion yet.
No sentiment analysis available yet.
Endpoints News@endptsGSK is paying up to $750M for Chimagen's trispecific T cell engager, its second deal with the Chinese biotech, this time in multiple myeloma.
—
Not ranked yet
—
Not ranked yet